|
WO2015157636A1
(en)
|
2014-04-10 |
2015-10-15 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
|
|
JP6599450B2
(ja)
|
2014-10-02 |
2019-10-30 |
アメリカ合衆国 |
がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
|
|
EP3075389A1
(en)
*
|
2015-03-31 |
2016-10-05 |
Technische Universität München |
T cell receptors and peptides derived by mutations for the treatment of cancer
|
|
WO2016179006A1
(en)
|
2015-05-01 |
2016-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
WO2017048614A1
(en)
|
2015-09-15 |
2017-03-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood
|
|
MA45595A
(fr)
|
2016-07-07 |
2019-05-15 |
Iovance Biotherapeutics Inc |
Protéines de liaison au ligand (1) de mort programmée (1) (pd-l1) et leurs procédés d'utilisation
|
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
|
HUE066460T2
(hu)
|
2016-10-26 |
2024-08-28 |
Iovance Biotherapeutics Inc |
A kriokonzervált tumor infiltráló limfociták restimulációja
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
KR102618948B1
(ko)
|
2016-11-17 |
2023-12-27 |
이오반스 바이오테라퓨틱스, 인크. |
잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
|
|
CA3049165A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
US11254913B1
(en)
|
2017-03-29 |
2022-02-22 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
CN110612446B
(zh)
*
|
2017-03-31 |
2023-07-04 |
美国卫生和人力服务部 |
分离新抗原-特异性t细胞受体序列的方法
|
|
MY206158A
(en)
|
2017-05-24 |
2024-12-02 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
AR112072A1
(es)
|
2017-06-05 |
2019-09-18 |
Iovance Biotherapeutics Inc |
Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
|
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
KR20250037592A
(ko)
*
|
2017-09-20 |
2025-03-17 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
돌연변이된 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체
|
|
SG11202002635RA
(en)
*
|
2017-09-29 |
2020-04-29 |
The United States Of America As Represented By The Secretary |
Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
|
|
WO2019067243A1
(en)
|
2017-09-29 |
2019-04-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T CELL RECEPTORS RECOGNIZING P53 MUTE
|
|
EP3691662A4
(en)
|
2017-10-06 |
2021-05-12 |
The University of Chicago |
SCREENING OF T LYMPHOCYTE FOR CANCER SPECIFIC ANTIGENS
|
|
CR20200251A
(es)
*
|
2017-11-17 |
2020-07-17 |
Iovance Biotherapeutics Inc |
Expansión de til de aspirados con aguja fina y biopsias por punción
|
|
WO2019112932A1
(en)
|
2017-12-04 |
2019-06-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of enriching cell populations for cancer-specific t cells using in vitro stimulation of memory t cells
|
|
US20210369775A1
(en)
*
|
2017-12-15 |
2021-12-02 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
EP3737743A1
(en)
|
2018-01-08 |
2020-11-18 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
CN112262212B
(zh)
*
|
2018-04-24 |
2024-07-12 |
美国卫生和人力服务部 |
使用羟基柠檬酸和/或其盐产生t细胞群体的方法
|
|
WO2019210131A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2019217753A1
(en)
*
|
2018-05-10 |
2019-11-14 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
CN110857319B
(zh)
*
|
2018-08-24 |
2023-12-08 |
杭州康万达医药科技有限公司 |
一种分离的t细胞受体、其修饰的细胞、编码核酸及其应用
|
|
CN109295097B
(zh)
*
|
2018-09-30 |
2020-09-25 |
北京鼎成肽源生物技术有限公司 |
一种mrfft2细胞
|
|
CN110093316A
(zh)
*
|
2018-09-30 |
2019-08-06 |
北京鼎成肽源生物技术有限公司 |
一种aff细胞的构建方法
|
|
CN110093317A
(zh)
*
|
2018-09-30 |
2019-08-06 |
北京鼎成肽源生物技术有限公司 |
一种lff2细胞的构建方法
|
|
CN109136284B
(zh)
*
|
2018-09-30 |
2020-12-29 |
北京鼎成肽源生物技术有限公司 |
一种afft2细胞
|
|
CN109294997B
(zh)
*
|
2018-09-30 |
2020-09-25 |
北京鼎成肽源生物技术有限公司 |
一种lrfft1细胞
|
|
CN110093373B
(zh)
*
|
2018-09-30 |
2021-05-07 |
北京鼎成肽源生物技术有限公司 |
一种afft2细胞的构建方法
|
|
CN109136183A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种rff2细胞的构建方法
|
|
CN109136268A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种lrff细胞的构建方法
|
|
CN109136277A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种lrfft2细胞的构建方法
|
|
CN109294982B
(zh)
*
|
2018-09-30 |
2020-11-06 |
北京鼎成肽源生物技术有限公司 |
一种rff2细胞
|
|
CN109294983A
(zh)
*
|
2018-09-30 |
2019-02-01 |
北京鼎成肽源生物技术有限公司 |
一种lff2细胞
|
|
CN109136281A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种mrfft1细胞的构建方法
|
|
CN109294998B
(zh)
*
|
2018-09-30 |
2020-11-06 |
北京鼎成肽源生物技术有限公司 |
一种rff1细胞
|
|
CN109136278B
(zh)
*
|
2018-09-30 |
2020-09-29 |
北京鼎成肽源生物技术有限公司 |
一种mrfft1细胞
|
|
CN109136280A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种lrfft1细胞的构建方法
|
|
CN109136279A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种mrfft2细胞的构建方法
|
|
CN109679917B
(zh)
*
|
2018-09-30 |
2020-09-25 |
北京鼎成肽源生物技术有限公司 |
一种lrfft2细胞
|
|
CN109136269A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种aff细胞
|
|
MY210603A
(en)
|
2018-11-05 |
2025-10-01 |
Iovance Biotherapeutics Inc |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
US12611427B2
(en)
|
2018-11-05 |
2026-04-28 |
Iovance Biotherapeutics, Inc. |
Treatment of NSCLC patients refractory for anti-PD-1 antibody
|
|
AU2020226498A1
(en)
|
2019-02-19 |
2021-10-14 |
Turnstone Biologics Corp. |
Methods for producing autologous T cells useful to treat cancers and compositions thereof
|
|
EP3935175A4
(en)
|
2019-03-04 |
2023-01-04 |
University Health Network |
T-LYMPHOCYTE RECEPTORS AND METHODS OF USE THEREOF
|
|
CN111748028A
(zh)
*
|
2019-03-29 |
2020-10-09 |
天津亨佳生物科技发展有限公司 |
一种针对egfr l858r基因突变的特异性t细胞受体及其应用
|
|
CN111748027A
(zh)
*
|
2019-03-29 |
2020-10-09 |
天津亨佳生物科技发展有限公司 |
一种针对egfr l858r基因突变的特异性t细胞受体及其应用
|
|
CN111748029B
(zh)
*
|
2019-03-29 |
2022-12-13 |
苏州蓝马医疗技术有限公司 |
一种针对egfr l858r基因突变的特异性t细胞受体及其应用
|
|
CN111848782A
(zh)
*
|
2019-04-25 |
2020-10-30 |
天津亨佳生物科技发展有限公司 |
一种针对egfr l858r基因突变的特异性t细胞受体及其应用
|
|
WO2020263919A1
(en)
*
|
2019-06-24 |
2020-12-30 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes
|
|
US12558424B2
(en)
|
2019-08-07 |
2026-02-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cells having enhanced anti-tumor activity
|
|
US20230032934A1
(en)
|
2019-11-27 |
2023-02-02 |
Myst Therapeutics, Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
|
US12516291B2
(en)
|
2019-12-11 |
2026-01-06 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
|
|
CN111019959B
(zh)
*
|
2019-12-30 |
2022-09-13 |
北京立康生命科技有限公司 |
一种体外转录mRNA的核苷酸分子、呈递细胞及应用
|
|
EP4512828A3
(en)
|
2020-02-27 |
2025-05-14 |
Turnstone Biologics Corp. |
Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
|
|
AU2021239379A1
(en)
|
2020-03-20 |
2022-10-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating T cells and T-cell receptors from peripheral blood by single-cell analysis for immunotherapy
|
|
CA3171559A1
(en)
|
2020-03-20 |
2021-09-23 |
Sri Krishna |
Methods of isolating t-cells and t-cell receptors from tumor by single-cell analysis for immunotherapy
|
|
CN115997008A
(zh)
|
2020-04-22 |
2023-04-21 |
艾欧凡斯生物治疗公司 |
协调用于患者特异性免疫疗法的细胞的制造的系统和方法
|
|
CA3158133A1
(en)
|
2020-04-28 |
2021-11-04 |
Lyell Immunopharma, Inc. |
Methods for culturing cells
|
|
CN112133372B
(zh)
*
|
2020-08-18 |
2022-06-03 |
北京臻知医学科技有限责任公司 |
抗原特异性tcr数据库的建立方法及抗原特异性tcr的评估方法
|
|
WO2022055946A1
(en)
|
2020-09-08 |
2022-03-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell phenotypes associated with response to adoptive cell therapy
|
|
JP2023546359A
(ja)
|
2020-10-06 |
2023-11-02 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
|
|
KR102751115B1
(ko)
*
|
2020-10-20 |
2025-01-09 |
연세대학교 산학협력단 |
단일 세포 분석법을 이용한 tcr-항원의 특이성을 확인하는 방법
|
|
JP2024512029A
(ja)
|
2021-03-25 |
2024-03-18 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
|
|
JP2025512401A
(ja)
|
2022-04-15 |
2025-04-17 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
|
|
JP2025537148A
(ja)
*
|
2022-11-04 |
2025-11-14 |
ターンストーン バイオロジクス コーポレイション |
ネオ抗原反応性腫瘍浸潤リンパ球を生成するための組成物および方法
|
|
WO2025080865A1
(en)
|
2023-10-11 |
2025-04-17 |
Turnstone Biologics Corp. |
Combination of tumor infiltrating lymphocytes (til) and low dose radiation
|
|
US12612821B2
(en)
|
2024-04-16 |
2026-04-28 |
LuxWall, Inc. |
Vacuum insulated panel with improved thermal performance proximate edge of glass during asymmetric thermal conditions
|